

FOR IRB USE ONLY

IRB ID #: 202011101-1001 APPROVAL DATE: 12/21/20 RELEASED DATE: 12/21/20 EXPIRATION DATE: 12/09/21



Clinical Trial for COVID-19 Treatment

# Researchers at Washington University School of Medicine are testing an

investigational medicine for adults who have symptoms in the early course of Coronavirus treatment.

## What is the purpose of this study?

STOP COVID Trial aims to slow the progression of COVID-19 and prevent hospitalization. The study is contactless meaning volunteers can participate without leaving home.

You may be eligible if you:

Are age 18 or older

Tested positive for COVID-19 Are experiencing symptoms

## Am I eligible to participate?

You are ineligible if you:

Are experiencing severe symptoms that require hospitalization

Are unable to take the study medication, fluvoxamine

## What will happen if I choose to participate?

If you are eligible and choose to participate:

You may be asked to take fluvoxamine or placebo for approximately 15 days and log symptoms two times per day.

Your participation may last approximately 3 months. You will be compensated up to $50 for your time.

## How do I learn more and see if I may qualify?

If you have tested COVID-19 positive, Immediately call us at (314) 747-1137,

Email us at stopcovidtrial@wustl.edu, or

Visit us online at [http://stopcovidtrial.wustl.edu](http://stopcovidtrial.wustl.edu/)

(314) 747-1137 | stopcovidtrial@wustl.edu | [http://stopcovidtrial.com](http://stopcovidtrial.com/)